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Immunobiology Lab, Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain
Myeloid C-type lectin receptors (CLRs) comprise a family of receptors expressed by
immune myeloid cells that share homologous C-type lectin domains. The implication
of these CLRs in the regulation of homeostasis and activation of myeloid cells has
generated a buoyant growth in the number of studies involving these receptors. Since
their first description, diverse nomenclature has been used to refer to each of them,
ranging from systematic classifications, such as gene name or cluster of differentiation,
to non-systematic ones that include terminology based on gene expression patterns
or function. In this review, we aim to summarize the different names used for the main
myeloid CLRs and analyze which of them have beenmore frequently used in the literature.
In addition, we have examined the evolution of the terminology applied to these myeloid
CLRs over time. Based on this analysis, we propose a consensus alias for each of
those myeloid CLRs. However, we acknowledge that systematicity is required beyond
this terminology based on use frequency. Therefore, we have included gene names as
the standardization tool to gather the maximum agreement. We suggest that a standard
nomenclature consisting of both gene names and consensus alias should be included
at least in scientific abstracts, which would help to identify relevant literature, saving time
and effort and fostering the research in this field in a more systematic manner.
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BROAD DIVERSITY OF MYELOID C-TYPE LECTIN RECEPTORS
AND BABYLONIAN CONFUSION IN THEIR NAMING
Innate immune cells surveil their nearby microenvironment, reacting against different challenges
when they are identified. This reaction is based in a toolbox consisting of a plethora of pattern
recognition receptors (PRRs) capable of sensing both pathogen-associated molecular patterns
(PAMPs) present in invading microbes (1) and damage-associated molecular patterns (DAMPs),
which are molecules released by stressed or necrotic cells (2). Ligation of PRRs by their ligands
initiates intracellular signaling pathways that modulate innate and adaptive immune responses.
Among the described PRRs, we will focus here in C-type lectin receptors (CLRs) expressed by
myeloid cells such as monocytes, macrophages, or dendritic cells.
C-type lectin receptors (CLRs) comprise a large family of metazoan proteins (more than
1,000) characterized by containing at least one C-Type Lectin-like Domain (CTLD) (3). In order
to organize the large number of receptors included in this superfamily, diverse classifications
have been proposed. CLRs were early classified into 17 groups based on their structure (3).
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As the functional relevance of this structural classification is
limited, an alternative classification of myeloid transmembrane
CLRs was proposed based on their intracellular signaling
domains, namely Immunoreceptor Tyrosine-based Activation
Motif (ITAM) domains, hemITAM domains, Immunoreceptor
Tyrosine-based Inhibition Motif (ITIM) domains or CLRs
without clear ITAM or ITIM domains (4, 5).
Moreover, the abundance and diversity in function and
expression of myeloid CLRs has also contributed to a great
dispersion in the way that researchers name these receptors.
These myeloid CLRs were initially named based on their
expression pattern or gene location (e.g., DEndritic cell-
associated C-type lecTIN-1 for Dectin-1 (6), Dendritic cell
NK lectin Group Receptor-1 for DNGR-1 (7), Macrophage-
INducible C-type LEctin for MINCLE (8). Later on, a
serial nomenclature was adopted for the naming of genes
from the CLR family, based on their common domain,
so that they are all cataloged as CLEC (C-type LECtin)
followed by an alphanumerical identifier (9). In an attempt
to avoid confusion when identifying surface markers, Human
Leukocyte Differentiation Antigen Workshops were organized
to standardize the naming of markers that are recognized
by specific monoclonal antibodies. The result of this effort
was the definition of the cluster of differentiation (CD)
nomenclature (10), which also applies to CLRs, such as CD303
for CLEC4C/BDCA-2 (11). The last of these workshops hold in
2014 represented the tenth of these events and provided CD
nomenclature for some more CLRs, reaching the CD371 for
CLEC12A (12).
This diverse nomenclature used for myeloid CLRs may
generate confusion when searching or disseminating information
as illustrated for CLRs expressed on dendritic cells, where
up to seven different names can be found for some of
these receptors (13). In an attempt to systematically analyze
potential solutions to this Babylonian confusion in the myeloid
CLR field, we have herein listed the different names used to
identify myeloid CLRs at the National Center for Biotechnology
Information (NCBI) database (https://www.ncbi.nlm.nih.gov).
We have studied the prevalence of each of these names and
the evolution of their usage over time in title, abstract, and
keywords of published works. We decided to delimit the
survey to these sections of the manuscripts as they are the
main sections where scientists search literature of their interest
using the PubMed search tool from NCBI (14). Taking into
account this information, we propose a standard nomenclature
consisting of a consensus alias for each myeloid CLR based
on the most frequently used in the current literature. In
any case, our study illustrates the need for systematization
in the naming of myeloid CLRs, and thus we propose that
the gene name (based on the CLEC nomenclature) should
always accompany the “consensus” identifier at least in the
abstract. Importantly, the official nomenclature for naming of
human genes is provided by the Human Genome Nomenclature
Committee (HGNC) (www.genenames.org), while official mouse
gene names come from the Mouse Genome Informatics (MGI)
(www.informatics.jax.org).
ANALYSIS OF NAMES USED FOR
MYELOID CLRS
In order to study the use of the different denominations, we
selected a list of myeloid CLRs grounded on our former review
on the flexibility of these sensors to trigger different signaling
pathways (5). Based on the “Gene” resource of NCBI (https://
www.ncbi.nlm.nih.gov/gene/) we listed all the potential names
(aliases) used for the mouse and human version of each selected
receptor, performing the search based on their gene names,
and organizing the CLRs based on their functional intracellular
domains as previously proposed (4, 5) (Figure 1).
Next, we completed a search based on the PubMed resource
of NCBI (https://www.ncbi.nlm.nih.gov/pubmed/, performed
along the second and third week of March 2019) for any of the
provided aliases for each receptor. The scope of this survey was
to obtain the total number of references where each specific name
has been used either alone or combined with other aliases for
the same CLR, generating usage frequencies for each of these
terms (Figure 1). Colored bars represent names used in more
than 5% of total articles referring to that CLR, except for gene
names as a source of systematicity, which are always depicted
in red independently of their frequency. An additional layer of
confusion for naming myeloid CLRs relies on the use or not of
hyphens in their names. For our study, those aliases found in
both versions were clustered as a single search using the “OR”
command (Figure 1).
A quick view clearly illustrates the variability of alias type
across CLRs. It can range from receptors always appointed
with the same alias, either their gene (CLEC12B) or alternative
(DCAR1) name, to members identified with up to five different
aliases in frequencies over 5% such as CLEC10A, CD301,
MGL, CD301a, and MGL1 (and even found named as HML
or CLECSF14 in minor proportions). This dispersion occurs
regardless the classification based on intracellular domains.
This analysis highlights the need for a systematic
nomenclature for myeloid CLRs. This is particularly important
for those receptors expressed by diverse coding genes in different
species, but commonly found with a shared alias. This is the case
of ITIM-bearing DCIR, encoded by CLEC4A in humans and
by Clec4a2 in mice. In both cases, DCIR is one of the accepted
aliases and is thus an unspecific name. Contrarily, and still using
DCIR as an example, some names exclusively designate the
human (LLIR) or mouse (DCIR1) receptors, but these aliases
are not among the most frequent. Therefore, for our study, we
have distinguished between “human DCIR” and “mouse DCIR,”
as they are encoded by genes with a different name. These same
criteria were applied to an additional name for DCIR, CLECSF6,
also shared for human and mouse receptors. In addition, mouse
DCIR is linked to several isoforms, mainly those encoded by the
genes Clec4a2 and Clec4a4 and literature on these isoforms may
be confusing if the genes are not named.
The use of non-official aliases, even not included at the NCBI
gene database, constitutes another anomalous situation. This is
the case for the non-ITAM/ITIM coupled CD207, commonly
known as LANGERIN, with CD207 used in 43,82% of references
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FIGURE 1 | Usage frequencies of the different aliases provided by NCBI for every myeloid C-type lectin receptor surveyed in this review. Receptors are grouped
based on their intracellular domain and listed in alphabetical order of their gene name. Colored bars represent names with usage frequencies higher than 5%, except
for gene names, which are always in red regardless their prevalence.
in PubMed and LANGERIN in the remaining 56,17%. Taking
this into account, for this receptor in particular, we have
performed our analysis including both names, even the one not
recorded as a gene alias at the Gene tool (LANGERIN). The
name LANGERIN comes from the specific expression of this
CLR by Langerhans cells. These cells show unique intracellular
structures called Birbeck granules whose presence is associated
with LANGERIN/CD207 expression (15). Therefore, this CLR
can be found both intracellularly and extracellularly (16). Taking
this into account, we wondered whether the use of LANGERIN
or CD207 correlates with the detection of the receptor by
histologic methods often used for intracellular staining or flow
cytometry, usually more associated to extracellular detection.
To approach it, we crossed in Pubmed either LANGERIN or
CD207 with “histology” or “flow cytometry.” Interestingly, both
aliases weremore frequently found associated to histology (84,6%
for LANGERIN and 82,86% for CD207). The same happened
when the search was performed combining LANGERIN AND
CD207 (84.7%). This would mean that histologic techniques are
preferred for studies involving this CLR and that both names are
used indistinctly.
A combination of these circumstances occurs for the ITAM-
coupled DECTIN-2. According to the Gene resource, DECTIN-
2 or DECTIN2 refers only to the product of the human
CLEC6A gene but not to the mouse Clec4n. However, it is quite
common to find references in the literature quoting DECTIN-
2 for the mouse version, which can be specifically found as
NKCL. Still, CLEC4N is also recorded as an alternative name for
the human version. Therefore, we have differentiated between
“human DECTIN-2 or DECTIN2” and “mouse DECTIN-
2 or DECTIN2,” applying the same criteria to CLEC4N
and CLEC6A.
Another representative example of the divergence in mouse
and human terms for a myeloid CLR is DC-SIGN, a member
of these receptors not coupled to an identifiable ITAM/ITIM
domain. The genes encoding for this receptor are named
differently in human (CD209) and mouse (Cd209a). DC-
SIGN/DCSIGN can be widely found referring to both forms,
consequently, we have also differentiated between “human DC-
SIGN or human DCSIGN” and “mouse DC-SIGN or mouse
DCSIGN.” In this case, the mouse receptor is specifically
identified as SIGNR1 or SIGN-R1, but CD209 is also considered
an alias for the mouse version. Therefore, we have differentiated
between human and mouse CD209 for our analysis. In any
case, to some extent, we assume some overlapping on the
results generated by these searches based on “human” or
“mouse.” It is interesting to see how this CLR was initially
described as a membrane-associated mannose-binding receptor
for the HIV gp120 protein (17), with no specific name
until it was first identified as DC-SIGN (18). Therefore,
our analysis applies to the use of different nomenclatures
for CLRs, although biological information about some of
them could have been generated before their current names
were coined.
It is also worthy to comment that the frequency of
use of a name can be influenced by the contribution
of a particular author to the study of a CLR, specially
when the literature is not abundant. Therefore, the most
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frequently used nomenclature may be biased by the publishing
frequency of one author on a particular CLR. This notion
emphasizes the need for an agreement in the way of naming
myeloid CLRs.
Indeed, in light of the results shown in Figure 1, it is clear
that defining a systematic manner to refer to myeloid CLRs is
mandatory. In that sense, we encourage that, independently of
how we prefer naming our favorite myeloid CLR, we should all
FIGURE 2 | Temporal analysis of the use of different aliases for ITAM- and hemITAM-coupled myeloid C-type lectin receptors. The frequency of each name was
analyzed either alone or in combination with the alternative aliases.
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include the gene name (as listed in Figure 1) to unequivocally
and systematically identify the receptor, both in the abstract and
the first time that they are mentioned in the text.
NOMENCLATURE EVOLUTION OF
MYELOID C-TYPE LECTIN RECEPTORS
Our proposal assumes that there are some common and
traditionally used nomenclatures that do not include the
systematicity provided by the gene name. To define the temporal
evolution of preferred names for myeloid CLRs, we analyzed the
usage of these names (included in Figure 1) in the last years,
which could suggest a consensus alias for each myeloid CLR.
We analyzed the number of works naming a particular term
either in the title, abstract, or keywords of published works. The
search results were exported and a table including complete title,
abstract, and keywords for each of the found items was generated
using the reference manager software JabRef (www.jabref.org).
Note that for each CLR, we incorporated the “NOT” command
to search for literature where each specific alias had been used
exclusively, but not the other aliases. We determined the use of
each alias in any of these three sections for every paper. For
the sake of clarity and unless it applies to gene names, we only
analyzed aliases with frequencies over 5% for timeline analysis.
Next, by using the “AND” command, we analyzed the number
of simultaneous appearances among the selected aliases, in order
to study their combined usage. Results are shown in Figure 2 for
ITAM- or hemITAM-coupled myeloid CLRs, Figure 3 for ITIM-
bearing and Figure 4 for those receptors that do not bear any
ITAM or ITIM domain. Those receptors with a single alias in
Figure 1 have not been included in this study.
Timeline analysis may not completely match the results
included in Figure 1; Jabref exploits the Machine readable digital
library (Mr. DLib) for their searches while PubMed search engine
is based on the Medical subjet headings (MeSH) algorithm
(19). This fact could introduce some variability. On the other
hand, the analysis performed in Figure 1 did not include the
“NOT” command; therefore, those references where a myeloid
CLR is identified by two (or more) aliases, were included in
the total number accounting for both names. However, in the
temporal analysis, those examples will be only included in the
combinations, identified by the use of the “AND” command.
The CLR devoid of ITAM/ITIM motif MRC1 is a representative
example, where all quotations in the temporal analysis using this
identification are combined with other aliases. This would also
suggest the inclusion of a consensus alias at least, in the abstract
of manuscripts, because if we consider the growing amount of
literature that we need to handle, representative abstracts are
becoming fundamental for the selection of relevant papers in
scientific research.
As indicated above, hyphens have been used almost randomly
in some aliases to separate name and numbers. Both versions are
documented in Figure 1 as, for example, BDCA-2 or BDCA2. For
this reason, we included both styles in the temporal analysis, and
only the most prevalent version is depicted in Figures 2–4. This
study illustrates that for all the instances except SIGNR3/SIGN-
R3 and SIGNR1/SIGN-R1, the version including hyphen is
the predominant one and consequently, we encourage its use.
The limitation in the number of characters accepted in certain
FIGURE 3 | Use of different names along time for myeloid C-type lectin receptors bearing an ITIM motif in their intracellular domain. The frequency of each alias was
analyzed either alone or in combination with their alternatives.
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FIGURE 4 | Usage evolution of different aliases for C-type lectin receptors not coupled to an identifiable ITAM or ITIM motif in their intracellular domain. The frequency
of each name was analyzed either alone or in combination with the alternative aliases.
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To facilitate identification, both gene name and alias should be named in the abstract of
the manuscript.
journals might be behind the use of names lacking the hyphen.
However, authors should adhere to consensus aliases to make
their research more easily identifiable.
The temporal analysis illustrates that common names have
been more frequently used than gene names as a systematic
manner to identify myeloid CLRs. CLEC9A vs. DNGR-1
represent the only exception of a CLR more often identified
by its gene name. The use of CLEC9A is extended as a gene
marker for cDC1s (20, 21), while the use of DNGR-1 is linked
to functional studies on this receptor (22, 23). CLEC5A shows a
peculiar behavior, with virtually the same frequency for exclusive
use of either the gene name orMDL-1 or the combination of both
of them.
In general, gene names and main aliases are not combined
together in the abstract, as we propose, which contributes to
confusion. Thus, as indicated before, the same common name
(DC-SIGN) has been applied to the mouse and human versions
without distinction, although they are encoded by different genes
and show different expression patterns (24).
Interestingly, the study of the temporal evolution also
allows for the detection of preferred names for CLRs along
the time, which could be an extra criterium to propose a
consensus alias. In this line, it is remarkable the use of
the cluster of differentiation nomenclature for some receptors
such as CLEC4C/CD303, CLEC10A/CD301, Mgl2/CD301b,
MRC1/CD206, and LY75/CD205. Once defined in a HLDA
workshop, their frequencies overcame any of their other
aliases. The best example is CD206 for the mannose receptor
MRC1, used both alone and in combination with other aliases.
This is because the first reference to a CD occurs after
monoclonal antibodies are submitted to a HLDA workshop
and, from there onwards, the use of the CD nomenclature
for a specific receptor begins to be applied for multiple
applications (25).
PROPOSAL OF CONSENSUS
NOMENCLATURE FOR MYELOID CLRS
Considering all our analysis, Table 1 compiles our proposal for
the consensus alias that should be used when referring to any
myeloid CLRs surveyed in this review. This proposal is based
both in the total frequency (Figure 1) and temporal evolution
(Figures 2–4) of their usage. In order to introduce systematicity,
we propose that the current most frequent alias should be
always accompanied by the specific gene name. Furthermore, we
encourage the use of hyphens when required, as they are more
frequently used.
Both the gene name and the proposed consensus alias
(Table 1) should appear at least in the abstract of manuscripts
or meetings. This practice would facilitate the identification of
literature of interest, fostering the visibility of any work in their
research field.
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